The management of dyspnea in cancer patients: a systematic review
- 1.5k Downloads
Goals of work
The goal of the study is to evaluate the effectiveness of four drug classes (opioids, phenothiazines, benzodiazepines, and systemic corticosteroids) for relieving dyspnea experienced by advanced cancer patients.
Materials and methods
A systematic literature review was conducted to July 2006. Search sources included MEDLINE, EMBASE, HealthSTAR, CINAHL, and the Cochrane Library. Four reviewers selected evidence using predefined criteria: controlled trials not limited to cancer and involving the specified drug classes for dyspnea treatment.
Three systematic reviews, one with meta-analysis, two practice guidelines, and 28 controlled trials were identified. Most examined the effect of opioids, generally morphine, on dyspnea. Although the results of individual trials were mixed, the systematic review with meta-analysis detected a significant benefit for dyspnea with systemic opioids; two small placebo-controlled trials in cancer patients found systemic morphine reduced dyspnea, and dihydrocodeine also significantly reduced dyspnea in four placebo-controlled trials. Nebulized morphine was not effective in controlling dyspnea in any study or the meta-analysis. No controlled trials examined systemic corticosteroids in the treatment of cancer patients, and of the other non-opioid drugs examined, only oral promethazine, a phenothiazine, showed some benefit in the relief of dyspnea. Studies varied in methodological quality.
Systemic opioids, administered orally or parenterally, can be used to manage dyspnea in cancer patients. Oral promethazine may also be used, as a second-line agent if systemic opioids cannot be used or in addition to systemic opioids. Nebulized morphine, prochlorperazine, and benzodiazepines are not recommended for the treatment of dyspnea, and promethazine must not be used parenterally.
KeywordsSystematic review Dyspnea Treatment Cancer
The Program in Evidence-Based Care is supported by, but editorially independent of, Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care. No potential conflicts of interest with regard to this review were declared by the authors.
- 5.Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218Google Scholar
- 9.Buck C, Laier-Groeneveld G, Criee CP (1996) The effect of dihydrocodeine and terbutaline on breathlessness and inspiratory muscle function in normal subjects and patients with COPD [abstract]. Eur Respir J 9:344sGoogle Scholar
- 11.Davis CL (1996) Single-dose randomized controlled trial of nebulized morphine in patients with cancer-related breathlessness [abstract]. Palliative Med 10:64–65Google Scholar
- 12.Donnelly S, Walsh D (1995) The symptoms of advanced cancer. Sem Oncol 22(2 Suppl 3):67–72Google Scholar
- 16.Finnish Medical Society Duodecim (2005) Palliative treatment of cancer. EBM guidelines. Evidence-based medicine.Helsinki, Finland: Duodecim Medical Publications LtdGoogle Scholar
- 18.Institute for Safe Medication Practices (2006) Action needed to prevent serious tissue injury with IV promethazine. Available at: http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp Accessed: 17 Oct 2006
- 19.Jadad AR (1998) Randomized controlled trials. BMJ, LondonGoogle Scholar
- 23.Johnson MA, Woodcock AA, Geddes DM (1983) Dihydrocodeine for breathlessness in “pink puffers”. Br Med J (Clin Res Ed) 286:675–677Google Scholar
- 26.Krouse RS, Rosenfeld KE, Grant M, Aziz N, Byock I, Sloan J et al (2004) Palliative care research: issues and opportunities. Cancer Epidmiol Biomarkers Prev 13:337–339Google Scholar
- 37.Peterson GM, Young RS, Dunne PF, Galloway JG, Parks TE (1996) Pilot study of nebulised morphine for dyspnoea in palliative care patients. Aust J Hosp Pharm 26:545–547Google Scholar
- 38.Polosa R, Simidchiev A, Walters EH (2002) Nebulised morphine for severe interstitial lung disease. Cochrane Database of Systematic Reviews Issue 3.:Art. No.:CD002872. DOI 10.1002/14651858.CD002872
- 43.Vickers AJ, Feinstein MB, Deng GE, Cassileth BR (2005) Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491]. BMC palliative care 4:5:DOI 10.1186/1472-684X-4-5
- 44.Wickham R, Malec M (2003) Management of dyspneaPeer viewpoint. J Support Oncol 1:32–34Google Scholar
- 45.Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE (2005) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews Issue 1.:Art. No.: CD001288. DOI 10.1002/14651858.CD001288.pub2